April 2016 Volume 12, Issue 4
Volume 12, Issue 4 | April 2016
April 2016
In this Issue
Discovery
Microbiome magic
Synlogic-AbbVie collaboration to use synthetic biotics to develop IBD drugTaking on the undruggables
PhoreMost and Wistar seek to de-orphan new targets in oncology, aging and immunologyCompugen seeks to usher in ‘new era’ in oncology
Company identifies binding partner for CGEN-15029 and moves closer to IND filingNot your Jedi’s ‘LIGHTSABR’
Scripps Florida researchers develop a cheap, portable drug discovery systemPeptides for immunology and immuno- oncology
New biotech startup focuses on next generation therapeutic peptides in oncology, immuno-oncology and immune diseasesResearch & Development
RNA and HIV
In exploring methylation in HIV, researchers uncover a key to its replicationBreaking membrane barriers
Microfluidic device could quicken DNA insertion into bacteriaCobra strikes with CPI to advance regenerative medicines
UK’s Cobra Biologics and CPI join hands to develop industrial manufacturing platform, advance regenerative medicinesBoosting research on organisms
DNASTAR releases Lasergene 13 software to enhance RNA researchTSRI and JCVI scientists call stem cell techniques ‘safe’
New research indicates the act of creating iPSCs for clinical use is unlikely to pass on cancer-causing mutations to patientsDiagnostics
CTE diagnostic test studied in NFL players
Recent developments may allow for chronic traumatic encephalopathy to be tested in live humansAge more than just a number in breast cancer
Screening for breast cancer needs to consider age, suggests new studyPromise of personalized medicine
Invivoscribe-Thermo collaboration seeks to help diagnose blood malignanciesNew findings on fungal asthma
A multi-organization team identifies 19 genetic variants related to susceptibility and damage riskEditor's Focus
Gene genie dilemma?
We don’t need to put genomics ‘back in the bottle,’ but we may need to bottle up expectationsCommentary
Phenotype beats genotype; measurements beat guessing
Have we entered into such a love affair with the promise of genetic data that we've unfairly and unwisely begun to neglect things like basic chemistry?Guest Commentary: New frontiers for target ID in oncology--Where will the next generation of targets come from?
Cancer therapy is fast approaching a clinical crossroads: to treat a cancer patient with an approach based on stimulating an immune response or to target the cancer cells directly with cytotoxic or a targeted therapy?Special Reports
Special Report on Neuroscience: Ease the pain
Analgesia remains a chronic challengeFeature
Show Preview: Immunology 2016--Immunologically speaking
Immunology 2016: Immunologically speakingBusiness & Government Policy
A ‘Blueprint’ for success for cancer immunotherapy
Roche and Blueprint Medicines collaborate to combine former’s cancer immunotherapy expertise with latter’s drug discovery platform and immunokinase expertiseSpark Therapeutics acquires Genable Technologies
Spark adds new program for leading cause of inherited retinal diseaseOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsFor your approval
A collection of recent regulatory approvals and other actions globallyClinical Trials
Fighting degenerative disease
Mesoblast develops portfolio of mesenchymal cells to target multiple medical needs1 DNA Way paves way to FDA
The Lancet publishes Genentech study on Actemra for remission in patients with giant cell arteritisA different kind of toolkit
MRCT team develops Ethics Tool Kit as guidelines for clinical research protocolsALZ-801 poised for next step against Alzheimer’s
Alzheon announces efficacy analyses of prior tramiprosate Phase 3 studies on key clinical endpoints in Alzheimer’s diseaseViiV announces Phase 2 results for injectable regimen for HIV-1 treatment
32-week maintenance data at Conference on Retroviruses and Opportunistic Infections showed comparable viral suppression between injectable regimen and three drug oral regimenPreclinical
Much-improved mouse models
Taconic addresses cross-species issues to create mouse model with human-like immune systemRelief from Rett?
Study suggests Phase 2 Alzheimer’s drug could treat rare Rett syndromePancreatic cancer vaccine shows promise
OncoQR’s TYG100 elicits strong immune response in all treated individualsImproving on CIK CAR-T
Formula and Rockland collaborate to develop C.I.K. CAR pipeline for cancerContract Services
A partner for Phase 3
Actinium selects Medpace as CRO for pivotal Iomab-B clinical trialSynexus expands to U.S.
The U.K. SMO has acquired Dallas-based Research Across AmericaCrown to commercialize prostate cancer models
University of York’s unique collection of PDX models to be applied to drug development
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Getting to the heart of drug safety testing
High throughput optical scanning enhances cardiac ion channel analysis for safer drug development.
Harnessing CRISPR-Cas9: Knocking out genes in myeloid cells
Explore the applications of CRISPR-Cas9 technology in therapeutic development for Alzheimer’s disease.
Harnessing liver-on-a-chip models for drug safety
Discover how researchers leverage microphysiological systems in toxicology studies.
